Despite the diagnostic and therapeutic advances made in multiple sclerosis (MS) over the past two decades, there remain essential areas of uncertainty and controversy in the field pertaining to prognosis, the nature of MS progression, and the perennial "clinico-radiological paradox." One fundamental concept that informs all three of these debates-a concept as old as the field of clinical neurology as we know it-is that symptomatology maps to lesion location in the nervous system. Location of lesions in the cervical spinal cord has been shown to predict disability and confer prognostic significance in MS, 1 the clinically isolated syndrome (CIS), 2 and in radiologic isolated syndrome (RIS). 3 There are, however, inconsistent data on precisely how spinal cord lesion burden impacts time to disability, 4 though as discussed in a recent commentary in Multiple Sclerosis Journal, both symptomatic and initially asymptomatic spinal cord lesions may confer a similar risk of future disability. 5 The clinicoradiologic paradox may at least in part be explained on this basis: overall brain lesion burden fails to correlate with disability 6 because these are not the lesions principally causative of the motor impairment prioritized by scales like the Expanded Disability Status Scale (EDSS) score. We have been looking in the wrong place.
In their prior work on "progressive solitary sclerosis," Keegan et al. 7 have demonstrated that one critically placed demyelinating lesion, typically affecting the corticospinal tract in an eloquent area without extensive redundancy, like the upper cervical spinal cord, may be the principal driver of progressive motor disability. In the current issue of Multiple Sclerosis Journal, the authors expand this concept by studying a cohort of patients followed longitudinally whose imaging demonstrates up to five lesions characteristic of MS in whom progressive motor disability can similarly be attributed to one critically located cord lesion. 8 They identified 38 patients meeting inclusion criteria who were followed from 18 to 442 months and found that progressive motor impairment could be explained by the critically placed lesion in all cases, the vast majority of which were in the cervical spinal cord or cervical/medullary junction.
Although (as with progressive solitary sclerosis) this particular population may not be highly prevalent or representative of the broader MS population, these patients can be particularly instructive. Unlike prognostic studies of lesion burden in cohorts with a diverse and potentially extensive number of symptomatic and asymptomatic lesions, the authors' use of highly restricted central nervous system (CNS) demyelinating disease allows for a relatively pure pool of patients from which the significance of a particular lesion can be tracked. While not designed to specifically evaluate the prognostic impact of the critically located lesion (noting the wide range of time to EDSS 6 from 16 to 190 months), this study does make a case for the phenomenological significance of lesion localization in MS, as the laterality and clinical symptoms of each patient were fully explained by the tract involvement and laterality of the causative lesion. That the specific clinical features of a patient's disability progression could be mapped to lesion location may be an important missing piece in our ability to model and predict disease course.
The topographical model of MS proposes that disability in progressive MS is the result of an insidious unmasking of deficits referable to underlying focal lesions. 9 This conceptualization is based on depicting the location of an individual patient's lesions in the form of a topographical map of MS disease burden, taking into account laterality and functional system involvement, in an effort to explicate the clinical heterogeneity inherent to the disease. In this model, the nervous system's capacity to keep disease burden submerged under the clinical threshold is depicted as a pool of compensatory reserve, with the spinal cord-a region with relatively little redundancy and capacity for organizational plasticity-occupying the "shallow end." 10 As reserve declines, the clinical threshold falls, gradually revealing clinically the deficits referable to critically located lesions. The work "Location, location, location" These data provide preliminary evidence that mapping lesion topography to the clinical picture may allow for early predictors of MS clinical course in an individually nuanced way. We have begun to utilize the topographical model of MS to identify a target neurologic deficit that can serve as a leading indicator of progression in individual patients. Like the Keegan et al.'s study, our recently presented pilot project 11 also utilized corticospinal tract signs as a marker of continued progression, making use of the quantifiable nature and high salience of the motor functional system. However, progressive motor impairment may simply be the most literal manifestation of localizable deficits in MS, and other investigators have sought to link lesion location with other specific physical and cognitive disability scores with variable degrees of success. 12, 13 While localization of lesions based on clinical findings is fundamental to the practice of clinical neurology, the Keegan et al. study utilized a blinded radiologist to select the most likely critical lesion in order to avoid bias that could be conferred by an awareness of the clinical presentation. Further studies will be essential to answer a larger question this study was not designed to address: if critically located lesions are indeed necessary or sufficient to yield a progressive clinical course. Future studies could be designed to include all patients in a cohort with progression, to evaluate how many of them have an identifiable critically located lesion; and all patients in a cohort with a critically located lesion could be evaluated to assess how many of them indeed progress. Similarly, it would be interesting to assess in future studies if a critically located lesion drives progression irrespective of the total number of lesions. The relevant pathophysiology of these prognostically important lesions remains to be elucidated, to determine if specific markers of lesion severity, tract integrity, and volumetric analyses could allow for earlier and more individualized identification of progressive disease.
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